User:Tkadm30/Notebook/Cannabidivarin: Difference between revisions
From OpenWetWare
< User:Tkadm30 | Notebook
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==ALS== | ==ALS== | ||
* "Identifying the primary site of pathogenesis in amyotrophic lateral sclerosis – vulnerability of lower motor neurons to proximal excitotoxicity" [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348560/ PMID] | |||
* Study: Neuronal hyperexcitability in Amyotrophic Lateral Sclerosis (ALS) [https://www.ncbi.nlm.nih.gov/pubmed/23626643 PMID] | * Study: Neuronal hyperexcitability in Amyotrophic Lateral Sclerosis (ALS) [https://www.ncbi.nlm.nih.gov/pubmed/23626643 PMID] | ||
* Is CBDV a potent antiglutamatergic drug ? [https://www.ncbi.nlm.nih.gov/pubmed/18781981 PMID] | * Is CBDV a potent antiglutamatergic drug ? [https://www.ncbi.nlm.nih.gov/pubmed/18781981 PMID] | ||
Revision as of 04:32, 14 July 2015
ALS
- "Identifying the primary site of pathogenesis in amyotrophic lateral sclerosis – vulnerability of lower motor neurons to proximal excitotoxicity" PMID
- Study: Neuronal hyperexcitability in Amyotrophic Lateral Sclerosis (ALS) PMID
- Is CBDV a potent antiglutamatergic drug ? PMID
Epilepsy
- Chemically induced neuronal hyperexcitability?
- CBDV activate phospholipase C-mediated TRPV1 channel PMID
